tegafur has been researched along with Response Evaluation Criteria in Solid Tumors in 5 studies
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a phase 2 study aimed at evaluating the efficacy and safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 in patients with advanced gastric cancer (AGC)." | 3.01 | A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604). ( Fukutani, M; Hirano, N; Ikeno, T; Kambe, M; Kawazoe, A; Keisho, C; Nakamura, Y; Nomura, S; Saito, Y; Sato, A; Shitara, K; Takahari, D; Tamura, H; Wakabayashi, M, 2021) |
| "We evaluated the efficacy and safety of 5-weekly S-1 and cisplatin combined with trastuzumab, a monoclonal antibody against human epidermal growth factor receptor type 2 (HER2) for HER2-positive advanced gastric cancer (AGC)." | 2.82 | A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. ( Adachi, K; Hirano, A; Hirata, Y; Joh, T; Kataoka, H; Kawai, T; Kitagawa, M; Mizuno, Y; Mizushima, T; Mochizuki, H; Mori, Y; Nakamura, M; Natsume, M; Nishie, H; Sano, H; Seno, K; Shimura, T; Sobue, S; Tsuchida, K, 2016) |
| "However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis." | 1.62 | Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. ( Ye, Y; Zheng, S, 2021) |
| " The aim of the present study is to evaluate the efficacy and safety of apatinib combined with S-1 as the second-line therapy for AGC patients." | 1.62 | Apatinib combined with S-1 as second-line therapy in advanced gastric cancer. ( Chen, M; He, H; Qin, R; Qiu, ZY; Tian, GY; Wang, Y; Xi, Y; Zhang, Z, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Y | 1 |
| Zheng, S | 1 |
| Kawazoe, A | 1 |
| Takahari, D | 1 |
| Keisho, C | 1 |
| Nakamura, Y | 1 |
| Ikeno, T | 1 |
| Wakabayashi, M | 1 |
| Nomura, S | 1 |
| Tamura, H | 1 |
| Fukutani, M | 1 |
| Hirano, N | 1 |
| Saito, Y | 1 |
| Kambe, M | 1 |
| Sato, A | 1 |
| Shitara, K | 1 |
| Qiu, ZY | 1 |
| Qin, R | 1 |
| Tian, GY | 1 |
| Zhang, Z | 1 |
| Chen, M | 1 |
| He, H | 1 |
| Xi, Y | 1 |
| Wang, Y | 1 |
| Wada, T | 1 |
| Yoshikawa, T | 1 |
| Sekine, S | 1 |
| Kamiya, A | 1 |
| Hayashi, T | 1 |
| Otsuki, S | 1 |
| Yamagata, Y | 1 |
| Katai, H | 1 |
| Kataoka, H | 1 |
| Mori, Y | 1 |
| Shimura, T | 1 |
| Nishie, H | 1 |
| Natsume, M | 1 |
| Mochizuki, H | 1 |
| Hirata, Y | 1 |
| Sobue, S | 1 |
| Mizushima, T | 1 |
| Sano, H | 1 |
| Mizuno, Y | 1 |
| Nakamura, M | 1 |
| Hirano, A | 1 |
| Tsuchida, K | 1 |
| Adachi, K | 1 |
| Seno, K | 1 |
| Kitagawa, M | 1 |
| Kawai, T | 1 |
| Joh, T | 1 |
2 trials available for tegafur and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male | 2021 |
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combina | 2016 |
3 other studies available for tegafur and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancre | 2021 |
Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Therapy, Combination; | 2021 |
Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biomarkers; Cape | 2022 |